超强增强剂驱动的IRF2BP2被主转录因子激活,并维持T-ALL细胞生长和存活
Juanjuan Yu1, Zimu Zhang2, Yanling Chen1
1Children's Hospital of Soochow University, Suzhou, 215003, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|October 25, 2024
概括
研究人员在T细胞急性淋巴细胞白血病 (T-ALL) 中发现了一种新的超级增强剂 (SE),它驱动瘤基因IRF2BP2. 这一发现揭示了T-ALL的新型治疗标,影响细胞生长和存活.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 超级增强剂 (SE) 调节对细胞身份至关重要的基因.
- 瘤特异性SE可以激活瘤基因,推动癌症的发展.
- 识别SE驱动的瘤基因对于癌症研究至关重要.
研究的目的:
- 在T细胞急性淋巴细胞白血病 (T-ALL) 中识别新的SE区域.
- 调查IRF2BP2在T-ALL病变发生中的作用.
- 阐明T-ALL中SE的监管机制.
主要方法:
- 在T-ALL患者样本和细胞系中发现一个新的SE区域.
- 产生IRF2BP2条件淘汰赛小鼠.
- 在体外和体内生物功能测定.
- 在目标下切割和标记 (CUT&Tag) 和免疫沉试验.
主要成果:
- 确定了一种新型的SE,激活IRF2BP2表达,受ERG,ELF1和ETS1.1等T-ALL主转录因子 (TF) 的调节.
- IRF2BP2在T-ALL细胞生长和存活中起着至关重要的作用,对正常的T细胞发育的影响最小.
- 在T-ALL细胞中,IRF2BP2损失会影响MYC和E2F通路.
- IRF2BP2与主TF合作,针对RAG1增强器,调节其表达.
结论:
- 在T-ALL.中确定了一个新的SE-IRF2BP2监管轴.
- IRF2BP2对于T-ALL的进展和生存至关重要.
- 这项研究为T-ALL监管网络提供了新的见解,并确定了潜在的治疗点.
相关概念视频
Master Transcription Regulators
6.9K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
General Transcription Factors
5.2K
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
5.2K
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
Somatic to iPS Cell Reprogramming
2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K


